IFNA1 and systemic lupus erythematosus: In the current study, we have addressed the above questions directly in a cohort of patients with SLE, treated or not with HCQ, to determine the predominant circulating cell subpopulation capable of IFN-α production and the extent to which such production is inhibited by HCQ in vivo.